RET Feb 4, 2022 CHOP Researchers Find Gene Fusions are Harbingers of Aggressive Disease in Pediatric Thyroid Cancer Premium Jan 24, 2022 Applied Pharmaceutical Science RET Inhibitor IND Gets FDA Clearance Nov 29, 2021 NICE Recommends Eli Lilly's Retsevmo for RET-Altered NSCLC Through Cancer Drugs Fund Nov 19, 2021 European Commission Approves Roche's Gavreto for RET Fusion-Positive NSCLC Oct 1, 2021 UK's NICE Recommends Selpercatinib for RET-Altered Thyroid Cancers Through Cancer Drugs Fund Jul 29, 2021 Blueprint Medicines Q2 Revenues Increase More Than 200 Percent May 20, 2021 Blueprint Medicines, Genentech to Discuss With Regulators Gavreto's Activity in RET-Altered Tumors May 14, 2021 LUNGevity Aims for Widespread Comprehensive Biomarker Test Access With New Patient-Facing Campaign Premium Apr 13, 2021 AACR Study of Eli Lilly's Retevmo Shows Anti-Tumor Activity Across Cancers Apr 6, 2021 Turning Point Therapeutics Shares Initial Data on RET Inhibitor, Anticipates FDA Meeting Jan 13, 2021 Swiss Firm Helsinn Doses First Patient in Phase I/II Tumor-Agnostic RET Inhibitor Trial Dec 14, 2020 Daiichi Sankyo, AstraZeneca Begin Phase II Datopotamab Deruxtecan Trial in NSCLC Dec 2, 2020 Genentech, Blueprint Medicines' Gavreto Receives FDA Approval in RET-Altered Thyroid Cancer Premium Sep 14, 2020 COVID-19 Experience Spurs Cancer Research Community to Embrace Telemedicine-Enabled Trials Sep 8, 2020 FDA Approves Thermo Fisher Scientific CDx for Genentech's Gavreto in NSCLC Patients With RET Fusions Sep 5, 2020 FDA Approves Blueprint Medicines, Genentech's Gavreto for RET-altered NSCLC Jul 14, 2020 Roche to Pay $775M to Blueprint Medicines for Rights to Pralsetinib for RET-Altered Tumors Jul 1, 2020 Blueprint Medicines Files NDA for Pralsetinib for RET-Driven Thyroid Cancers Jun 2, 2020 Blueprint's Positive Pralsetinib Data Places New Option on Horizon for RET-Altered Cancer Patients Premium May 11, 2020 FDA Approves Lilly's Retevmo for RET-Driven Lung, Thyroid Cancers Load More Breaking News Marengo Therapeutics Begins Phase I/II Trial of Selective T-Cell-Targeted Antibody Janssen, Legend Biotech's Carvykti Bests Chemo in Earlier-Line Multiple Myeloma Trial In Brief This Week: PreludeDx, Johnson & Johnson, Syros, Magenta, Merck NICE Backs Gilead Sciences' Yescarta as Third-Line Option for Lymphoma Patients BMS Eyeing Breyanzi Indications in CLL, SLL After Positive Trial Data Enhertu Approved in Europe for HER2-Low Metastatic Breast Cancer
